胸苷酸合成酶与肿瘤

doi:10.3760/cma.j.cn371439-20200318-00088

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (10): 615-618.doi: 10.3760/cma.j.cn371439-20200318-00088

胸苷酸合成酶与肿瘤

黄志国, 胡孔旺()

安徽医科大学第一附属医院普外科胃肠外科,合肥 230022

收稿日期:2020-03-18 修回日期:2020-04-26 出版日期:2020-10-08 发布日期:2020-11-20
通讯作者: 胡孔旺 E-mail:hukw@sina.com
基金资助:
安徽省省级质量工程项目(2017jyxm1073);吴阶平医学基金会临床科研专项资助基金(320.6750.19092-19);安徽省科技厅重点研究与开发计划项目(202004j0702003)

Thymidylate synthase and tumor

Huang Zhiguo, Hu Kongwang()

Department of General Gastrointestinal Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Received:2020-03-18 Revised:2020-04-26 Online:2020-10-08 Published:2020-11-20
Contact: Hu Kongwang E-mail:hukw@sina.com
Supported by:
Quality Engineering Project of Anhui Provincial of China(2017jyxm1073);Special Fund for Clinical Research of Wujieping Medical Foundation(320.6750.19092-19);Key Research and Development Project of Science and Technology Department of Anhui Province of China(202004j0702003)

摘要/Abstract

摘要：

胸苷酸合成酶(TS)是DNA合成中的关键酶,常常作为化疗药物作用靶点。TS在多种肿瘤(如非小细胞肺癌、结直肠癌、乳腺癌等)中的表达与患者的临床预后及化疗药物耐药密切相关。通过各种分子机制降低肿瘤组织中TS的表达成为提高化疗疗效及改善临床预后的重要手段。

关键词: 肿瘤, 抗药性, 胸苷酸合酶

Abstract:

Thymidylate synthase (TS) is a key enzyme in DNA synthesis and is often used as a target for chemotherapy drugs. In a variety of tumors such as non-small cell lung cancer, colorectal cancer, breast cancer, etc, the expression of TS is closely related to the clinical prognosis and chemotherapy drug resistance of patients. Reducing the expression of TS in tumor tissues through various molecular mechanisms has become an important means to improve the efficacy of chemotherapy drugs and improve the clinical prognosis.

Key words: Neoplasms, Drug resistance, Thymidylate synthase

黄志国, 胡孔旺. 胸苷酸合成酶与肿瘤[J]. 国际肿瘤学杂志, 2020, 47(10): 615-618.

Huang Zhiguo, Hu Kongwang. Thymidylate synthase and tumor[J]. Journal of International Oncology, 2020, 47(10): 615-618.

参考文献 33

[1]	Li XY, Liang JW, Mohamed OK, et al. Design, synjournal and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs[J]. Eur J Med Chem, 2018,154:267-279. DOI: 10.1016/j.ejmech.2018.05.020. pmid: 29807332
[2]	Lu GQ, Li XY, Mohamed OK, et al. Design, synjournal and biological evaluation of novel uracil derivatives bearing 1, 2, 3, -triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs[J]. Eur J Med Chem, 2019,171:282-296. DOI: 10.1016/j.ejmech.2019.03.047.
[3]	Kang M, Zheng W, Chen Q, et al. Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma[J]. Cancer Lett, 2018,419:40-52. DOI: 10.1016/j.canlet.2018.01.026. pmid: 29331423
[4]	Wang L. Mitochondrial purine and pyrimidine metabolism and beyond[J]. Nucleosides Nucleotides Nucleic Acids, 2016,35(10-12):578-594. DOI: 10.1080/15257770.2015.1125001.
[5]	Kulda V, Hrda K, Houdek Z, et al. Predictive significance of thymidylate synthase expression in non-small cell lung cancer[J]. Anticancer Res, 2017,37(12):6953-6958. DOI: 10.21873/anticanres.12161. doi: 10.21873/anticanres.12161 pmid: 29187479
[6]	Yang M, Fan WF, Pu XL, et al. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy[J]. J Chemother, 2017,29(2):106-112. DOI: 10.1080/1120009X.2016.1254940.
[7]	Miura K, Oba T, Hamanaka K, et al. FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells[J]. Oncotarget, 2019,10(11):1171-1192. DOI: 10.18632/oncotarget.26622. doi: 10.18632/oncotarget.26622 pmid: 30838090
[8]	Chamizo C, Zazo S, Dómine M, et al. Thymidylate synthase expre-ssion as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer[J]. BMC Pulm Med, 2015,15:132. DOI: 10.1186/s12890-015-0132-x.
[9]	Kuo WT, Tu DG, Chiu LY, et al. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase[J]. Oncol Rep, 2017,38(5):2787-2795. DOI: 10.3892/or.2017.5951.
[10]	Chen CY, Chen YY, Chen JJW, et al. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression[J]. Oncotarget, 2017,8(37):61901-61916. DOI: 10.18632/oncotarget.18717. pmid: 28977913
[11]	Liao KS, Wei CL, Chen JC, et al. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells[J]. Regul Toxicol Pharmacol, 2016,81:353-361. DOI: 10.1016/j.yrtph.2016.09.031. doi: 10.1016/j.yrtph.2016.09.031 pmid: 27693704
[12]	Tung CL, Chen JC, Wu CH, et al. Salinomycin acts through redu-cing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells[J]. Exp Cell Res, 2017,357(1):59-66. DOI: 10.1016/j.yexcr.2017.04.026. doi: 10.1016/j.yexcr.2017.04.026 pmid: 28454878
[13]	Ko JC, Chen JC, Yen TC, et al. Nitroglycerin enhances cisplatin-induced cytotoxicity via AKT inactivation and thymidylate synthase downregulation in human lung cancer cells[J]. Pharmacology, 2020,105(3-4):209-224. DOI: 10.1159/000503688. pmid: 31630149
[14]	Bai W, Wu Y, Zhang P, et al. Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer[J]. Int J Clin Exp Pathol, 2015,8(10):12333-12345.
[15]	Jiang H, Li B, Wang F, et al. Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy[J]. Oncol Lett, 2019,18(2):1157-1162. DOI: 10.3892/ol.2019.10395.
[16]	Torén W, Ansari D, Andersson B, et al. Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment[J]. Future Oncol, 2018,14(4):343-351. DOI: 10.2217/fon-2017-0431. pmid: 29318904
[17]	Chen S, Yue T, Huang Z, et al. Inhibition of hydrogen sulfide synjournal reverses acquired resistance to 5-FU through miR-215-5p-EREG/TYMS axis in colon cancer cells[J]. Cancer Lett, 2019,466:49-60. DOI: 10.1016/j.canlet.2019.09.006. doi: 10.1016/j.canlet.2019.09.006 pmid: 31542354
[18]	Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells[J]. Carcinogenesis, 2019,40(3):422-431. DOI: 10.1093/carcin/bgy186. pmid: 30590435
[19]	Varghese V, Magnani L, Harada-Shoji N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expre-ssion[J]. Sci Rep, 2019,9(1):1505. DOI: 10.1038/s41598-018-38017-0. pmid: 30728402
[20]	Jiang B, Liu F, Liu Z, et al. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway[J]. Tumour Biol, 2016,37(7):9465-9472. DOI: 10.1007/s13277-015-4740-0. doi: 10.1007/s13277-015-4740-0 pmid: 26787540
[21]	Ahn JY, Lee JS, Min HY, et al. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expre-ssion in colon cancer[J]. Oncotarget, 2015,6(32):32622-32633. DOI: 10.18632/oncotarget.5327.
[22]	Zhou YH, Liu Y, Zhang W, et al. Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer[J]. Pathol Res Pract, 2019,215(11):152644. DOI: 10.1016/j.prp.2019.152644.
[23]	Shan F, Liu YL, Wang Q, et al. Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer[J]. Oncol Lett, 2018,16(3):3274-3280. DOI: 10.3892/ol.2018.8973. doi: 10.3892/ol.2018.8973 pmid: 30127925
[24]	Matsumoto A, Hayashida T, Takahashi M, et al. Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer[J]. Mol Med Rep, 2018,18(1):958-964. DOI: 10.3892/mmr.2018.9068.
[25]	Siddiqui A, Gollavilli PN, Schwab A, et al. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers[J]. Cell Death Differ, 2019,26(11):2223-2236. DOI: 10.1038/s41418-019-0289-6. doi: 10.1038/s41418-019-0289-6 pmid: 30737477
[26]	Li X, Kong X, Kong X, et al. 53BP1 sensitizes breast cancer cells to 5-fluorouracil[J]. PLoS One, 2013,8(9):e74928. DOI: 10.1371/journal.pone.0074928. doi: 10.1371/journal.pone.0074928 pmid: 24040364
[27]	Pereira MA, Ramos MFKP, Dias AR, et al. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy[J]. Chin J Cancer Res, 2018,30(5):526-536. DOI: 10.21147/j.issn.1000-9604.2018.05.06. pmid: 30510364
[28]	Wang D, Yu X, Wang X. High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis[J]. Int J Biol Markers, 2016,31(2):e101-e109. DOI: 10.5301/jbm.5000202. doi: 10.5301/jbm.5000202 pmid: 27012156
[29]	Donner DB, Nakakura EK, Venook AP, et al. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma[J]. PLoS One, 2019,14(7):e0219469. DOI: 10.1371/journal.pone.0219469. pmid: 31291332
[30]	Shimizu A, Kaira K, Yasuda M, et al. Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma[J]. Neoplasma, 2016,63(2):282-287. DOI: 10.4149/215-150714N389.
[31]	Burdelski C, Strauss C, Tsourlakis MC, et al. Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer[J]. Oncotarget, 2015,6(10):8377-8387. DOI: 10.18632/oncotarget.3107. doi: 10.18632/oncotarget.3107 pmid: 25762627
[32]	Fu Z, Jiao Y, Li Y, et al. TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer[J]. Medicine (Baltimore), 2019,98(51):e18487. DOI: 10.1097/MD.0000000000018487.
[33]	Intuyod K, Saavedra-Garcia P, Zona S, et al. FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance[J]. Cell Death Dis, 2018,9(12):1185. DOI: 10.1038/s41419-018-1235-0. pmid: 30538221

胸苷酸合成酶与肿瘤

Thymidylate synthase and tumor

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.